ORF_ID	Contig	Start	Stop	Orientation	Cut_Off	Pass_Bitscore	Best_Hit_Bitscore	Best_Hit_ARO	Best_Identities	ARO	Model_type	SNPs_in_Best_Hit_ARO	Other_SNPs	Drug Class	Resistance Mechanism	AMR Gene Family	Predicted_DNA	Predicted_Protein	CARD_Protein_Sequence	Percentage Length of Reference Sequence	ID	Model_ID	Nudged	Note	Hit_Start	Hit_End	Antibiotic
BGC0000231.1|Griseusin_1 # 3 # 146 # 1 # ID=1_1;partial=10;start_type=Edge;rbs_motif=None;rbs_spacer=None;gc_cont=0.646	BGC0000231.1|Griseusin_1 	3	146	+	Loose	1650	21.557	Bacillus subtilis mprF	40.0	3003324	protein homolog model	n/a	n/a	peptide antibiotic	antibiotic target alteration	defensin resistant mprF	ATCCAGAACTCCCGCAACGATCCGCGCTTCGTGCAGATCAGCCATGAACTCAAGCCGTTCATCGAGCCGTACGACCCGGAGACCTGGCGGACGCCGGCCGACGCGATGGCCACGCGCTTCTACGACTGGTCGGCAGGCGAGTGA	IQNSRNDPRFVQISHELKPFIEPYDPETWRTPADAMATRFYDWSAGE	MLIKKNALSILKIVFPIAVLLFVIYQSKKELTNLSFKRTLMVINGLERTDLFMLVLIGLLAVAAMSLYDYVLKYSLRLSITNGKVFRVSWIANSFNNVLGFGGLAGVGLRMMFYKEHTKDHKALVKGIAWLTSSMLLGLSVFSIFVAARVLPVDEVIHEKPWLWAVVIGFALILPLSLAVSKIKDRKAGDEENADKVKNPIFAYIGASVVEWLMAGTVIYFALFAMGIHADIRYVFGVFVIAAIGGMISLVPGGFGSFDLLFLLGMEQLGYHQEAIVTSIVLYRLAYSFIPFILGLFFAAGDLTENTMKRLETNPRIAPAIETTNVLLVVQRAVLVRILQGSLSLIVFVAGLIVLASVSLPIDRLTVIPHIPRPALLLFNGLSLSSALILLILPIELYKRTKRSYTMAITALVGGFVFSFLKGLNISAIFVLPMIIVLLVLLKKQFVREQASYTLGQLIFAVALFTVALFNYNLIAGFIWDRMKKVLRHEYFVHSTSHITHATIMAIIIVPLFFLIFTVVYHKRTKPIGEKADPERLAAFLNEKGGNALSHLGFLGDKRFYFSSDGNALLLFGKIARRLVVLGDPSGQRESFPLVLEEFLNEAHQKGFSVLFYQIEREDMALYHDFGYNFFKLGEEAYVDLNTFTLTGKKKAGLRAINNRFEREEYTFHVDHPPFSDAFLEELKQISDEWLGSKKEKGFSLGFFDPSYLQKAPIAYMKNAEGEIVAFANVMPMYQEGEISVDLMRYRGDAPNGIMDALFIRMFLWAKEEGCTSFNMGMAPLANVGTAFTSFWSERFAAVIFNNVRYMYSFSGLRAFKEKYKPEWRGKYLAYRKNRSLSVTMFLVTRLIGKSKKDSV	5.49	gnl|BL_ORD_ID|1987|hsp_num:0	1558			2403	2475	defensin
BGC0000231.1|Griseusin_2 # 190 # 1458 # 1 # ID=1_2;partial=00;start_type=GTG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.722	BGC0000231.1|Griseusin_2 	190	1458	+	Loose	750	193.741	Mycobacterium tuberculosis kasA mutant conferring resistance to isoniazid	34.9	3003463	protein variant model	F413L	n/a	isoniazid-like antibiotic	antibiotic target alteration	antibiotic resistant kasA	GTGGAACGCCGGGCAGTGATCACGGGAATCGGTGTGTGCGCACCGGGCGGAACCGGTGTGGACAGCTTCTGGGAGCTGATGTGCGACGGCCGGACGGCCACCCGCGGCATCACCCTCTTCGACCCGTCTCCGTACCGCTCCAGGGTCGCCGCCGAGATCGACTTCGACCCGCGGGCGCACGGGCTGACGCCGCAGGAGATCCGGCGGATGGACCGGGCCGCGCAGTTCGGCGTGGTGACGGCACGGGAGGCCTTCGCCGACAGCGGGCTCGACGGCGCCGCGCTCGATCCGTTCCGTACGGGAGTCAGCCTCGGCACCGCGATCGGCGCGGCCGGCGGCCTGGACGCGGAGTACCGCGTGGTCAGCGACGACGGCCGGCTGGAGCTGGTCGACCACCGGTACGCGACCCCGCATCTGTACGACCTGTTCGTGCCGAGCTCCTTCGCGACCGAAGTGGCCTGGGCCGTCGGCGCGGAAGGACCGGCGACGGTGGTGTCCACCGGCTGCACCGCCGGGATCGACGCGGTGGGCCACGCGGTGGAGGCGATCCGCGACGGCAGCGCCGATGTGATGGTCACCGGCGCGGTGGACGCGCCGATCACCCCGCTCACGATGGCGGCCTTCGACGCGATCCGCGCCACCACGTCCCTCAACGACGAGGCGGACACCGCCTCCCGCCCCTTCGACGCGTCACGCAAGGGCTTCGTCCTCGGTGAGGGGGCGGCGGTGTTCGTCCTGGAGGAGGCGGAGCACGCACGGCGCAGAGGCGCGTACGTGTACGCGGAGATCGCCGGATACGCCTCGCGCGGCAACGCCTTCCACATGACCGGACTGCGGTCCGACGGAGCGGAGCTGGCCGCCGCGATCCGGGCGGCGCTGGACGAGGCCCGGCTCGACGCGTCGGCGGTGGACTACGTCAACGCGCACGGTTCCGGCACCCGCCAGAACGACCGGCACGAGACGGTCGCGCTCAAGTCGGCTCTGGGACAGCACGCCCACCGGGTGCCGGTCAGCGCGATCAAGTCGATGGTCGGGCACTCGCTCGGGGCGATCGGCTCCATCGAGATCGCCGCCTGCGCACTGGCCATGCGGCACCACGTCATCCCTCCGACCGCCAATCTGCACACCCCGGATCCCGAGTGCGATCTCGACTATGTCCCGCTGACGGCCCGCGCGCAGCGCACCGATGCCGTCCTCACCATCGGCAGCGGATTCGGCGGCTTCCAGAGCGCGATGGTGCTGGCCCGTCCCGACAGGAGCGCCGCGTGA	MERRAVITGIGVCAPGGTGVDSFWELMCDGRTATRGITLFDPSPYRSRVAAEIDFDPRAHGLTPQEIRRMDRAAQFGVVTAREAFADSGLDGAALDPFRTGVSLGTAIGAAGGLDAEYRVVSDDGRLELVDHRYATPHLYDLFVPSSFATEVAWAVGAEGPATVVSTGCTAGIDAVGHAVEAIRDGSADVMVTGAVDAPITPLTMAAFDAIRATTSLNDEADTASRPFDASRKGFVLGEGAAVFVLEEAEHARRRGAYVYAEIAGYASRGNAFHMTGLRSDGAELAAAIRAALDEARLDASAVDYVNAHGSGTRQNDRHETVALKSALGQHAHRVPVSAIKSMVGHSLGAIGSIEIAACALAMRHHVIPPTANLHTPDPECDLDYVPLTARAQRTDAVLTIGSGFGGFQSAMVLARPDRSAA	MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAHAWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY	101.44	gnl|BL_ORD_ID|1968|hsp_num:0	1943			195	1245	isoniazid
BGC0000231.1|Griseusin_3 # 1455 # 2693 # 1 # ID=1_3;partial=00;start_type=GTG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.755	BGC0000231.1|Griseusin_3 	1455	2693	+	Loose	750	96.2857	Mycobacterium tuberculosis kasA mutant conferring resistance to isoniazid	29.62	3003463	protein variant model	F413L, G269S	n/a	isoniazid-like antibiotic	antibiotic target alteration	antibiotic resistant kasA	GTGAGCGCCCCGGGCGGCGGCGACCGCGGCCGCACGTTGATCACCGGCATGGGACTGGCCACACCGCACGGCGTCGACGTGGAGGATTTCTGGGCGGCGACACGGGTCGGCAAGAACGCCATCGGACCGGTCACCCGGTTCGACGCGTCCGGCTACCCGGCGCGGCTGGCGGGAGAGATCCGCGGATTCTCGGCCGCGGACCATCTGCCGGGCCGGCTGGTGGCGCAGACCGACCGGGTGACCCAACTGGCCCTGGTCGCCGCGGACCGCGCGTTCCGGGACGCCGGGGTGGCTCCGGGCGACCTTCCCGCGAACGGGATGGGCGTGGTCACGGCGGCCGGTTCCGGCGGTTTCGAGTTCGGCGAGCGGGAGTTGCGCAAGCTCTGGAGCCTCGGCGCGAACCACGTGAGCGCCTACCAGTCGTTCGCCTGGTTCCCGACCGCCAACACCGGCCAGATCGCGATCCGCAGCGACAGCCGCGGACCGAACGGCGTGGTCGTCGGCGACCAGGCCGGCGGCCTCGACGCGCTCGGACAGGCCCGGCGGCTCATCCGCCGCGGCACCGGACTGGTCGCCGCGGGCGGCTTCGAGGCGTCGCTGACACCGCTCGGCTGGACGGCACGGCTGTCGACCGGACTGATGTCGACCAGCGACGATCCCGACCGCGCCTATCTGCCGTTCCATCCGGCGGCGCGCGGCTACGTTCCCGGCGAGGGCGGCGCACTGCTGATCCTGGAGGACGAGCGCAGCGCCCTGGCCCGCGGCGCGGCCACCGCCCACGCCGAACTGGCCGGGTACAGCGCGACGCTGGATCCGCGCCCCGGCAGCGGGCGCGAGCCCGGTCTGCGGCGCGCCATCGAACTGGCGCTGGCGGACGCCGGCGTCGCACCGGCCGAGGTGGACGTCGTCTTCGCCGACGCCGCCGGCTCACCGGAGCCGGACGCGGTGGAAGTGGCGGCCGTGGCCGGTGTGTTCGGACCGCGCGCGGTGCCGGTCACCGCGCCGAAGACCATGATCGGCCGGCTCCAGGCGGGCGGCGCCCCGGTGGACGTGGTGACCGCCGTCCTCGCCATCCGCGAAGGCCTGATCCCGCCGACCGCCGACGCGGAGTCCGCCACGGCCCGCGAGCTGGACCTGGTCGTCGGACGGCCCCGGACCGCCTCGGTCGGCACCGCGCTGGTGCTCGCGCGAGGGCACGGCGGATTCAACTCGGCCGTCGTGCTGCGGGCCGTCGACTGA	MSAPGGGDRGRTLITGMGLATPHGVDVEDFWAATRVGKNAIGPVTRFDASGYPARLAGEIRGFSAADHLPGRLVAQTDRVTQLALVAADRAFRDAGVAPGDLPANGMGVVTAAGSGGFEFGERELRKLWSLGANHVSAYQSFAWFPTANTGQIAIRSDSRGPNGVVVGDQAGGLDALGQARRLIRRGTGLVAAGGFEASLTPLGWTARLSTGLMSTSDDPDRAYLPFHPAARGYVPGEGGALLILEDERSALARGAATAHAELAGYSATLDPRPGSGREPGLRRAIELALADAGVAPAEVDVVFADAAGSPEPDAVEVAAVAGVFGPRAVPVTAPKTMIGRLQAGGAPVDVVTAVLAIREGLIPPTADAESATARELDLVVGRPRTASVGTALVLARGHGGFNSAVVLRAVD	MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAHAWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY	99.04	gnl|BL_ORD_ID|1968|hsp_num:0	1943			81	1239	isoniazid
BGC0000231.1|Griseusin_4 # 2809 # 3078 # 1 # ID=1_4;partial=00;start_type=GTG;rbs_motif=GGA/GAG/AGG;rbs_spacer=5-10bp;gc_cont=0.674	BGC0000231.1|Griseusin_4 	2809	3078	+	Loose	400	24.2534	JOHN-1	40.0	3000840	protein homolog model	n/a	n/a	carbapenem; cephalosporin; penam	antibiotic inactivation	JOHN beta-lactamase	GTGTCCAAGCAGGAGTTCACCCTCGAAGACCTCAAGCGCATCCTTCTGGAAGGCGCCGGCGCGGACGAGGGCGTCGACCTCGACGGCGACATCCTCGACACCGATTTCGAGGAACTCGGCTACGAGTCGCTGGCGTTGCTGGAGACCGGCGGCCGGATCGAGCGCGAGTACGGGATCACGCTCGACGACGACGTGCTCGCCGACAGCCGCACGCCGCGCTCGCTGATAGCCGCCATCAACGCCGCGTTCCAGGGCCTCGTCGAGGCCTGA	MSKQEFTLEDLKRILLEGAGADEGVDLDGDILDTDFEELGYESLALLETGGRIEREYGITLDDDVLADSRTPRSLIAAINAAFQGLVEA	MRKLASIILFLAAVSNSLGQSKNSPLQISHLTGDFYVYRTFNDYKGTKISANAMYVVTDKGVVLFDAPWDKTQFQPLLDSIKAKHNKEVVMLFGTHSHEDRAGGFDFYKKKGIKTYSIKLTDDILKKNKEPRAEFIISNDTTFTVGNHTFEVYYPGKGHAPDNIVAWFKKEKILYGGCFVKSAEALDLGYLGDADVKEWQKSIKKVQAKFKKPDYIISGHDDWTSKESLNHTLKLVDEYLAQKSAGKK	35.89	gnl|BL_ORD_ID|297|hsp_num:0	222			339	399	
BGC0000231.1|Griseusin_5 # 3201 # 3986 # 1 # ID=1_5;partial=00;start_type=ATG;rbs_motif=GGAG/GAGG;rbs_spacer=5-10bp;gc_cont=0.704	BGC0000231.1|Griseusin_5 	3201	3986	+	Loose	750	37.3502	mdtH	26.27	3001216	protein homolog model	n/a	n/a	fluoroquinolone antibiotic	antibiotic efflux	major facilitator superfamily (MFS) antibiotic efflux pump	ATGTCGGATCAGGACAAGCGCGTCGCCGTCGTCACCGGAGCCACCAGCGGCATCGGACTGTCCGTCGCGCGCCTGCTGGCCTCACAGGGCCACCGTGTGTTCATCGGCGCGCGCAGCGCGGAGAACGTCGCCGCGACCGTCAAGGAGCTCGTGGCCGAGGGCCTCGACGTCGACGGCGCGGTGGTGGACGTCCGCAGCGACGCCGATGTCGAGGCCTGGATCCAGGCCGCCGTGGACCGCTTCGGCACCGTCGACGTCGTCGTCAACAACGCGGGCCGCTCCGGCGGCGGCGTCACCGCGGACATCGACCCGGAGCTGTGGCACGACGTCATCGACACCAATCTCAACTCGGTCTTCCGCGTCACGCGTTCGGCGCTGAACACCGGCGGCCTGCGGTCCAAGAGCCGCGGCCGGATCATCAACATCGCCTCCACGGCCGGCAAGCAGGGTGTGGTGCTCGGTGCGCCGTACTCCGCGTCCAAGCACGGCGTGGTCGGCTTCACCAAGGCGCTCGGCAACGAGCTGGCGCCGACCGGCATCACCGTCAACGCCGTCTGCCCCGGATACGTCGAGACGCCGATGGCGCAGCGCGTGCGGCAGGGGTACGCCGCGGCGTACGACGCCACCGAGGACGCGATCCTGGAGAAGTTCCAGGCGAAGATCCCGCTCGGCCGCTACTCCACGCCGGACGAGGTCGCCGGACTCGTCGGCTACCTGGCCTCGGACACCGCGGCCTCCATCACCTCGCAGGCGCTCAACGTCTGCGGCGGACTCGGCAACTTCTGA	MSDQDKRVAVVTGATSGIGLSVARLLASQGHRVFIGARSAENVAATVKELVAEGLDVDGAVVDVRSDADVEAWIQAAVDRFGTVDVVVNNAGRSGGGVTADIDPELWHDVIDTNLNSVFRVTRSALNTGGLRSKSRGRIINIASTAGKQGVVLGAPYSASKHGVVGFTKALGNELAPTGITVNAVCPGYVETPMAQRVRQGYAAAYDATEDAILEKFQAKIPLGRYSTPDEVAGLVGYLASDTAASITSQALNVCGGLGNF	MSRVSQARNLGKYFLLIDNMLVVLGFFVVFPLISIRFVDQMGWAAVMVGIALGLRQFIQQGLGIFGGAIADRFGAKPMIVTGMLMRAAGFATMGIAHEPWLLWFSCLLSGLGGTLFDPPRSALVVKLIRPQQRGRFFSLLMMQDSAGAVIGALLGSWLLQYDFRLVCATGAVLFVLCAAFNAWLLPAWKLSTVRTPVREGMTRVMRDKRFVTYVLTLAGYYMLAVQVMLMLPIMVNDVAGAPSAVKWMYAIEACLSLTLLYPIARWSEKHFRLEHRLMAGLLIMSLSMMPVGMVSGLQQLFTLICLFYIGSIIAEPARETLSASLADARARGSYMGFSRLGLAIGGAIGYIGGGWLFDLGKSAHQPELPWMMLGIIGIFTFLALGWQFSQKRAARRLLERDA	64.93	gnl|BL_ORD_ID|342|hsp_num:0	375			147	456	enoxacin; norfloxacin
BGC0000231.1|Griseusin_6 # 4051 # 5010 # 1 # ID=1_6;partial=00;start_type=ATG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.699	BGC0000231.1|Griseusin_6 	4051	5010	+	Loose	600	27.7202	OprZ	38.3	3004142	protein homolog model	n/a	n/a	macrolide antibiotic; fluoroquinolone antibiotic; aminoglycoside antibiotic; cephalosporin	antibiotic efflux	resistance-nodulation-cell division (RND) antibiotic efflux pump	ATGTCGCAGCCCGGCCTGCGCGAGGTGGAGCACGAGATCACGGTCTCCGCTCCCGCCGCCGCCGTCTACCGTCTGATCGCCGAGGTCCGCAACTGGCCCCGGATCTTCCCGCCGACCATCTACGTCGACCACGTCGAGGAGAACGGCGACGAGGAGCGCATCCGTATCTGGGCCACGGCCAACGACGAGGCCAAGAACTGGACCTCGCGCCGCACGCTGGACCCGGAAGGCCTGCGGATCACCTTCCGCCAGGAGGTTCCGGCGCCGCCGGTCGCCGCCATGGGCGGCGCCTGGATCATCGAGCCGCTCGGCGACGCCGAGTCACGGATCCGTCTGCTGCACGACTACCGCGCGGTCGACGACGACCCGGCGCACCTGGAGTGGATCGACCAGGCGGTCGACCGCAACTCCCGCTCCGAACTGGCGGCCCTGAAGGGCAACGTCGAGAAGGCGCACGCCGAGGAGGGGCTGACGTTCTCCTTCGAGGACACGGTGCGGGTCGACGGTGCGGCGAAGGACGTCTACGACTTCGTCAACGAGGCCGACCTGTGGCACGAGCGGCTGCCGCACGTCGCCACCGTACGGCTGCGCGAGGACACTCCCGGCCTCCAGGAGCTGGAGATGGACACCCGGGCCAAGGACGGCTCGACCCACACCACCAAGTCGTACCGGGTGACCTTTCCGCACCAGCGGATCGCCTACAAGCAGACCACGCTGCCGGCGCTGATGACCCTGCACACCGGCTACTGGACCTTCGCCGAGGACGACCGGGGCGTGCTGGCCTCCTCCCAGCACACGGTCACCATCAACACCGCCAACATCGCCCGCGTCCTCGGCCCGGAGGCCACCGTCGAGGACGCCAAGGCGTATGTGCACACCGCGCTGTCCACCAACAGCACGGCCACGCTGAACCACGCCAAGCGGTTCGCCGAGGAGCGTGCCGCGGGCCGGCGGGGCTGA	MSQPGLREVEHEITVSAPAAAVYRLIAEVRNWPRIFPPTIYVDHVEENGDEERIRIWATANDEAKNWTSRRTLDPEGLRITFRQEVPAPPVAAMGGAWIIEPLGDAESRIRLLHDYRAVDDDPAHLEWIDQAVDRNSRSELAALKGNVEKAHAEEGLTFSFEDTVRVDGAAKDVYDFVNEADLWHERLPHVATVRLREDTPGLQELEMDTRAKDGSTHTTKSYRVTFPHQRIAYKQTTLPALMTLHTGYWTFAEDDRGVLASSQHTVTINTANIARVLGPEATVEDAKAYVHTALSTNSTATLNHAKRFAEERAAGRRG	MKPVAMTLLALALSGCSLAPTHERPAAPVPAQYDTPAQPGQAAAPQDWRAYFNDPALQAWIAAALANNRDLRVAALRIEEARALYGVQQSERLPAIDASGEFSRGRATEPGQPRTPVSNRYRAAVGITAFELDFFGRVRSLSDAALARYLASEEAHRAATLALVAETATAYFNQRSLAEQLRLTDDTLALRETTLKLTQRRYDAGLETAIGLRTAQMLVESSRATRAELTREASLARHALGLLAGDFALPLGVDPTPLESQSLTPLAAGLPSELLTRRPDLRQAEQALRAANADIGAARAAFFPSVQLTTDIGTTADRFSDLFSGGTGGWSFAPRLTLPIFNAGRNRANLSLAETRKHIAVAQYEGSIQAAFRDVADALSARDALRDQIEAQRKVRDADRERQRLAERRYARGVANYLEMLEAQRSLFESEQEFIRLQQRRLVNAVDLYKALGGWDDGSSPAS	68.90	gnl|BL_ORD_ID|2408|hsp_num:0	2796			135	270	erythromycin; cefepime
BGC0000231.1|Griseusin_7 # 5013 # 5363 # 1 # ID=1_7;partial=01;start_type=GTG;rbs_motif=GGxGG;rbs_spacer=5-10bp;gc_cont=0.764	BGC0000231.1|Griseusin_7 	5013	5363	+	Loose	600	63.1586	Streptomyces venezuelae rox	40.0	3007209	protein homolog model	n/a	n/a	rifamycin antibiotic	antibiotic inactivation	rifampin monooxygenase	GTGCCGGAGGACGACGACGCGCGGATCGTCGTGGTCGGCGCGGGCCCGGTCGGGCTGCTGCTCGCCGGGCTGCTGCGCCGGTCCGGCGCGGACGTGGTCGTCCTCGAACAGCTCACCGCGCCCACCACCGAGTCCCGCGCCTCCACCCTGCACGCCCGCACCATGGAGATCCTCGACGGCTGCGGTGTGCGGGACCGGCTGGGCGCGGTGGAGCGCGAGCCGCGCGGGCACTTCGGCGGCATCGGCCTCGACCTGACGCTGCCCGTCCCCCGTCCGGGCCAGTGGAAGGTGCCGCAGACGCGGCTGGAGGAGGTGCTCGCGCGGTGGGCACGGGAGCTCGGTGTGCGGATC	MPEDDDARIVVVGAGPVGLLLAGLLRRSGADVVVLEQLTAPTTESRASTLHARTMEILDGCGVRDRLGAVEREPRGHFGGIGLDLTLPVPRPGQWKVPQTRLEEVLARWARELGVRI	MFDVIVVGGGPTGLMLAGELRLHGVRVLVLEKETEPTRQSRAQGLHVRSIEVMAQRGLLERFLERGHTVAVGGFFAGLATSWPERLDTAHSYVLAVPQVITEQLLAEHATALGAEIRRGRALVGLRQDEDGVTVDLADGEQLRARYVVGCDGGRSTVRKLLGVAFPGEPSRVETLLGEMEMTASQEELTSVMTEVRKTQQRFGAMPLGDGVFRVVVPAEGVAEDRTASPTLDEFKQQLRAHAGTDFGVHSPRWLSRFGDATRQAERYRVDRVFLAGDAAHIHPPTGGQGLNLGIQDAFNLGWKLAAEVDGWAPEGLLDTYHAERHPVATEVLDNTRAQIQLMSTEPGPQAVRRLMAELVEFENVNRYLIEKITAISVRYDVGEGHELLGRRMRDLALKHGRLYERMHEGRGLLLDQTGRLSVAGWEDRVDHVVEVSEELDVPAVLLRPDGHVVWAGEDQQELLTRMPAWFGAATAG	24.58	gnl|BL_ORD_ID|4833|hsp_num:0	5820			9	348	rifampin; rifaximin; rifapentine
